We are live on ! Find out more
WS

Wela Strategies Portfolio holdings

AUM $264M
1-Year Est. Return 16.32%
This Fund
S&P 500
This Quarter Est. Return
+4.87%
1 Year Est. Return
+16.32%
3 Year Est. Return
+51.28%
5 Year Est. Return
+48.35%
10 Year Est. Return
AUM
$264M
AUM Growth
+$10.3M
Cap. Flow
+$40.1M
Cap. Flow %
15.21%
Top 10 Hldgs %
77.82%
Holding
59
New
6
Increased
20
Reduced
23
Closed
4

No holdings matched the selected filter criteria.

Similar funds

Wela Strategies's Q3 2025 Portfolio in Review

As of Q3 2025, Wela Strategies held 59 positions worth $264M, up 4.1% from $253M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Wela Strategies deployed $40.1M of net new capital in Q3 2025, opening 6 new positions and adding to 20 existing holdings. Its largest new stake was AbbVie: 2,970 shares worth $688K.

By sector, the portfolio is most concentrated in Technology at 1.4% of assets, up from 1.2% a quarter earlier, followed by Industrials and Healthcare.

On the sell side, the largest reduction was iShares Core MSCI EAFE ETF, an estimated $2.96M trimmed.

  • Wela Strategies's largest Q3 2025 buy was AbbVie: 2,970 shares worth $688K.
  • Wela Strategies added most to VanEck Fallen Angel High Yield Bond ETF in Q3 2025, an estimated $41.8M increase.
  • Wela Strategies's biggest Q3 2025 reduction was iShares Core MSCI EAFE ETF, cutting an estimated $2.96M.
  • Wela Strategies fully exited Gilead Sciences in Q3 2025, selling an estimated $679K.
  • Wela Strategies's ten largest holdings make up 78% of its $264M portfolio in Q3 2025.
  • Wela Strategies opened 6 new positions and closed 4 in Q3 2025.
  • Wela Strategies's portfolio value rose 4.1% quarter-over-quarter to $264M.

Based on Wela Strategies's 13F filing for Q3 2025, filed 24 Oct 2025.